Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
By J. Mascola, G. Stiegler, T. VanCott, H. Katinger, C. Carpenter, C. Hanson, Holly Beary, Deborah Hayes, S. Frankel, D. Birx and 1 more. Nature Medicine, 2000
1,369 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/b744ddebf3406f1d552c4d1d5b3b8fa839687b76
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
In Virology
Citations in the corpus
- Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro (2001, background): “The studies of Mascola and colleagues described above are therefore of particular value (26).”
- Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies (2009, background): “Data from lentiviral animal models suggest that antibodies capable of neutralizing primary strains of HIV-1 may have the capacity to prevent HIV-1 infection (1, 28, 30, 35).”
- Glycan-Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies (2018, positive): “While passive administration of HIV-1-specific neutralizing antibodies in animal models can fully protect against infection (Gautam et al., 2016; Julg et al., 2017; Mascola et al., 2000; Nishimura et al., 2017; Saunders et al., 2015), the induction of such antibodies via immunization has not yet bee”
- Vaccine Adjuvants: Putting Innate Immunity to Work (2010, background): “…MPL are recognized specifically by TLR4, but MPL leads to signaling only through the TRIF adaptor, whereas LPS leads to TLR4 activation through both the TRIF and MyD88 pathways (Mata-Haro et al., 2007), the latter pathway resulting in high levels of many inflammatory cytokines, prominently TNF-a.”
- Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 (2001, background): “MAbs against HIV-1 have proven to be extremely powerful tools for a variety of applications including probing the structure and function of envelope glycoproteins (5, 18, 42, 78), exploring the antigenicity of novel HIV-1 vaccine candidates (8, 10, 77), and establishing the conditions for protection”
- Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1 (2014, background): “infection [8,9,10,11,12,13] and recently it was shown that a mAb”
- Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies (2005, background): “Neutralizing Abs are of particular interest because their presence at the time of intravenous, vaginal, and oral routes of live virus challenge has been shown to prevent AIDS virus infection in nonhuman primates (31, 65, 66, 69, 84, 105).”